scholarly journals Primary localized retroperitoneal sarcomas: report from Slovenian sarcoma referral center

2020 ◽  
Vol 18 (1) ◽  
Author(s):  
Marko Novak ◽  
Andraž Perhavec ◽  
Milena Kerin Povšič ◽  
Matej Arnuš ◽  
Darja Eržen
Keyword(s):  
High Volume ◽  
Soft Tissue Tumors ◽  
Retroperitoneal Sarcoma ◽  
Free Survival ◽  
Median Tumor Size ◽  
Compartmental Resection ◽  
Retroperitoneal Sarcomas ◽  
Local Recurrence Free Survival ◽  
Disease Specific

Abstract Background Sarcoma patients should be treated in high volume referral sarcoma centers. Compartmental resection is proposed as the best treatment option in retroperitoneal sarcoma patients. Methods Institute of Oncology Ljubljana is the only referral sarcoma center in Slovenia. Having a population of 2.1 million poses a unique situation. We manage all sarcoma patients in the country and operate on patients with soft tissue tumors of extremities, trunk, and abdomen. Data for all consecutive patients surgically treated from January 1999 to December 2018 for primary localized retroperitoneal sarcoma was extracted from a prospective surgical database. Data about the incidence of sarcoma patients in Slovenia was extracted from the Cancer Registry of Republic of Slovenia. Clinicopathologic variables and the outcome were analyzed. Results In total, 89 patients were included in the study. Median age was 62 years. Dedifferentiated liposarcoma was the most common histology (38.2%). Median tumor size was 21 cm. Compartmental resection was performed in 47.2% (42/89). Postoperative complication grade 3a or higher according to Clavien-Dindo classification had 30.3% (27/89) of patients. The 30-day and 90-day mortality rate was 2.2% and 5.6%. Median follow-up was 62.1 months. Corresponding 5-year overall survival was 67.2%, 5-year disease-specific survival was 72.6%, and 5-year local recurrence-free survival was 81.5%, respectively. Conclusion Results from our institution show that referral sarcoma centers may achieve very good results in management of retroperitoneal sarcoma patients, despite not meeting the criteria for high volume hospitals, as long as they have multidisciplinary team, appropriate facilities, and expertise.

scholarly journals Primary localized retroperitoneal sarcomas. Report from Slovenian sarcoma referral center.

2020 ◽  
Author(s):  
Marko Novak ◽  
Andraz Perhavec ◽  
Milena Kerin Povsic ◽  
Matej Arnus ◽  
Darja Erzen
Keyword(s):  
High Volume ◽  
Soft Tissue Tumors ◽  
Retroperitoneal Sarcoma ◽  
Free Survival ◽  
Median Tumor Size ◽  
Compartmental Resection ◽  
Retroperitoneal Sarcomas ◽  
Local Recurrence Free Survival ◽  
Disease Specific

Abstract Background: Sarcoma patients should be treated in high volume referral sarcoma centers. Compartmental resection is proposed as the best treatment option in retroperitoneal sarcoma patients. Methods: Institute of Oncology Ljubljana is the only referral sarcoma center in Slovenia. Having population of 2.1 million poses a unique situation. We manage all sarcoma patients in the country and operate on patients with soft tissue tumors of extremities, trunk and abdomen. Data for all consecutive patients surgically treated from January 1999 to December 2018 for primary localized retroperitoneal sarcoma was extracted from a prospective surgical database. Data about the incidence of sarcoma patients in Slovenia was extracted from the Cancer Registry of Republic of Slovenia. Clinicopathologic variables and the outcome were analyzed.Results: In total 89 patients were included. Median age was 62 years. Dedifferentiated liposarcoma was the most common histology (38.2 %). Median tumor size was 21 cm. Compartmental resection was performed in 47.2 % (42/89). Postoperative complication grade 3a or higher according to Clavien-Dindo classification had 30.3 % (27/89) of patients. The 30-day and 90-day mortality rate was 2.2 % and 5.6 %. Median follow-up was 62.1 months. Corresponding 5-year overall survival was 67.2 %, 5-year disease specific survival was 72.6 % and 5-year local recurrence-free survival was 81.5 %, respectively. Conclusion: Results from our institution show that referral sarcoma centers may achieve very good results in management of retroperitoneal sarcoma patients, despite not meeting the criteria for high volume hospitals, as long as they have multidisciplinary team, appropriate facilities and expertise.

scholarly journals Primary Localized Retroperitoneal Sarcomas: Report from Slovenian Sarcoma Referral Center.

2020 ◽  
Author(s):  
Marko Novak ◽  
Andraz Perhavec ◽  
Milena Kerin Povsic ◽  
Matej Arnus ◽  
Darja Erzen
Keyword(s):  
High Volume ◽  
Soft Tissue Tumors ◽  
Retroperitoneal Sarcoma ◽  
Recurrence Free Survival ◽  
Free Survival ◽  
Compartmental Resection ◽  
Retroperitoneal Sarcomas ◽  
Local Recurrence Free Survival ◽  
Disease Specific

Abstract Background: Sarcoma patients should be treated in high volume referral sarcoma centers. Compartmental resection is proposed as best treatment option in retroperitoneal sarcoma patients. Methods: Institute of Oncology Ljubljana is the only referral sarcoma center in Slovenia. Having population of 2.1 million poses a unique situation. We manage all sarcoma patients in the country and operate on patients with soft tissue tumors of extremities, trunk and abdomen. Data for all consecutive patients surgically treated from January 1999 to December 2018 for primary localized retroperitoneal sarcoma was extracted from prospective surgical database. Clinicopathologic variables and the outcome were analyzed.Results: In total 89 patients were included. Mean age was 59.2 years. Dedifferentiated liposarcoma was the most common histology (38.2 %). Mean tumor size was 23.5 cm. Compartmental resection was performed in 47.2 % (42/89). Postoperative complication grade 3a or higher according to Clavien-Dindo classification had 30.3 % (27/89) of patients. The 30-day and 90-day mortality rate was 2.2 % and 5.6 %. Median follow-up was 62.1 months. Corresponding 5-year overall survival was 67.2 %, 5-year disease specific survival was 72.6 % and 5-year local recurrence free survival was 81.5 %, respectively. Conclusion: Results from our institution show that referral sarcoma centers may achieve very good results in management of retroperitoneal sarcoma patients, despite not meeting the criteria for high volume hospitals, as long as they have multidisciplinary team, appropriate facilities and expertise.

Neoadjuvant chemoradiotherapy for patients with high-risk extremity and truncal sarcomas: A 10-year follow-up study.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 10058-10058
Author(s):  
Nicole Jannelle Look Hong ◽  
Francis J Hornicek ◽  
David C. Harmon ◽  
Edwin Choy ◽  
Yen-Lin Chen ◽  
...  
Keyword(s):  
High Risk ◽  
Survival Rates ◽  
Neoadjuvant Chemoradiotherapy ◽  
Soft Tissue Sarcomas ◽  
Clinicopathologic Characteristics ◽  
Free Survival ◽  
Median Tumor Size ◽  
Recent Cohort ◽  
Better Than

10058 Background: Patients with high-risk extremity and truncal soft tissue sarcomas (STS) are at considerable risk for recurrence. A regimen of preoperative mesna, doxorubucin hydrochloride (Adriamycin), ifosfamide, and dacarbazine (MAID), interdigitated with radiotherapy (RT), followed by resection and postoperative chemotherapy with or without RT, has demonstrated high rates of local and distant control. The goal of this series is to study outcomes of our most recent cohort of patients treated on this regimen. Methods: We retrospectively reviewed records of 55 consecutive patients with STS of the extremity or superficial trunk who completed all phases of treatment at our institution from January 2000–July 2011. Clinicopathologic characteristics and patient outcomes were analyzed. Results: Fifty-five patients were analyzed and had a median age of 53 years (range 18-73). The median tumor size was 10.1cm (range 2.5-35.5 cm). Twenty-seven (49%) and 28 (51%) patients had grade 2 and 3 tumors, respectively. Margins were negative in 49 (89%) patients, and positive in 6 (11%) patients. At a median follow-up of 43 months, there were 7 (13%) locoregional, and 17 (31%) distant recurrences. The local and distant 5-year recurrence-free survival (RFS) rates were 92% and 64%, respectively. The 5-year overall (OS) and disease-specific survival rates were 86% and 89%, respectively. There were no treatment-related deaths or secondary myelodysplasias. There were no significant predictors of OS or RFS. Conclusions: Outcomes of a contemporary cohort of patients with extremity and truncal STS treated with an intense regimen of neoadjuvant chemoradiotherapy and surgery are consistent with previous reports from our institution and better than reports of chemotherapy alone. [Table: see text]

Intraoperative versus external beam boost for breast cancer: A matched-pair analysis.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 1120-1120 ◽  
Author(s):  
Elena Sperk ◽  
Daniela Astor ◽  
Grit Welzel ◽  
Axel Gerhardt ◽  
Marc Suetterlin ◽  
...  
Keyword(s):  
Overall Survival ◽  
Local Recurrence ◽  
Breast Conserving Surgery ◽  
Matched Pair ◽  
Recurrence Free Survival ◽  
Free Survival ◽  
Matched Pair Analysis ◽  
Pair Analysis ◽  
Local Recurrence Free Survival

1120 Background: After breast conserving surgery, radiotherapy leads to a better overall survival. In addition to whole breast radiotherapy (WBRT) a boost to the tumor bed leads to a better local control. The tumor bed boost is usually added after WBRT or can be done intraoperative (IORT). Belletti et al. (Clin Cancer Res., 2008) described positive effects, an antitumoral effect and modulation of microenvironment after IORT with 50kV x-rays. A matched pair analysis was performed to investigate the impact of IORT boost on overall survival compared to standard external beam boost. Methods: Between 2002 – 2009, 370 patients were treated for breast cancer with WBRT + boost (external beam (EBRT) boost n = 146, IORT boost n =224). A matched pair analysis (1:1 propensity score matching for age, TNM, grading, hormonal treatment and chemotherapy) for overall survival and local recurrence free survival could be done for 53 pairs. All patients underwent breast conserving surgery and WBRT with 46-50Gy. 53 patients received an EBRT boost with 16Gy (2Gy/fraction, dedicated linear accelerator) and 53 patients received an IORT boost with 20Gy (INTRABEAM system, 50kV x-rays). Median follow-up was 6 months (range, 1-77 months) for the EBRT boost patients and 56 months (range, 2-97 months) for IORT boost patients. Kaplan Meier estimates were performed for overall survival and local recurrence free survival. Results: IORT boost patients had a longer follow-up than EBRT boost patients. Despite the difference in follow-up times, there was a strong trend towards better overall survival after IORT boost (90.2% vs. 62.3%, p = 0.375). One local recurrence was present in each group (EBRT boost after 15 months, local recurrence free survival 95%; IORT boost after 12 months, local recurrence free survival 98.1%). Conclusions: IORT given as a boost seems to have a positive impact on overall survival in breast cancer patients after breast conserving surgery. To identify such an effect a prospective randomized trial should be conducted.

scholarly journals Locally recurrent chondrosarcoma of the pelvis and limbs can only be controlled by wide local excision

2019 ◽  
Vol 101-B (3) ◽  
pp. 266-271 ◽  
Author(s):  
M. K. Laitinen ◽  
M. C. Parry ◽  
L-R. Le Nail ◽  
C. H. Wigley ◽  
J. D. Stevenson ◽  
...  
Keyword(s):  
Local Recurrence ◽  
Primary Tumour ◽  
Surgical Margin ◽  
Recurrence Free Survival ◽  
Disease Specific Survival ◽  
Univariable Analysis ◽  
Free Survival ◽  
Local Recurrence Free Survival ◽  
Disease Specific ◽  
Significant Factors

Aims The purpose of this study was to investigate the potential for achieving local and systemic control after local recurrence of a chondrosarcoma of bone Patients and Methods A total of 126 patients with local recurrence (LR) of chondrosarcoma (CS) of the pelvis or a limb bone were identified from a prospectively maintained database, between 1990 and 2015 at the Royal Orthopaedic Hospital, Birmingham, United Kingdom. There were 44 female patients (35%) and 82 male patients (65%) with a mean age at the time of LR of 56 years (13 to 96). The 126 patients represented 24.3% of the total number of patients with a primary CS (519) who had been treated during this period. Clinical data collected at the time of primary tumour and LR included the site (appendicular, extremity, or pelvis); primary and LR tumour size (in centimetres); type of operation at the time of primary or LR (limb-salvage or amputation); surgical margin achieved at resection of the primary tumour and the LR; grade of the primary tumour and the LR; gender; age; and oncological outcomes, including local recurrence-free survival and disease-specific survival. A minimum two years’ follow-up and complete histopathology records were available for all patients included in the study. Results For patients without metastases prior to or at the time of local recurrence, the disease-specific survival after local recurrence was 62.5% and 45.5% at one and five years, respectively. After univariable analysis, significant factors predicting disease-specific survival were grade (p < 0.001) and surgical margin (p = 0.044). After multivariable analysis, grade, increasing age at the time of diagnosis of local recurrence, and a greater time interval from primary surgery to local recurrence were significant factors for disease-specific survival. A secondary local recurrence was seen in 26% of patients. Wide margins were a good predictor of local recurrence-free survival for subsequent recurrences after univariable analysis when compared with intralesional margins (p = 0.002) but marginal margins did not reach statistical significance when compared with intralesional margins (p = 0.084) Conclusion In cases of local recurrence of a chondrosarcoma of bone, we have shown that if the tumour is non-metastatic at re-staging, an increase in disease-specific survival and in local recurrence-free survival is achievable, but only by resection of the local recurrence with a wide margin. Cite this article: Bone Joint J 2019;101-B:266–271.

Secondary chondrosarcoma arising from osteochondroma

2019 ◽  
Vol 101-B (10) ◽  
pp. 1313-1320 ◽  
Author(s):  
Yusuke Tsuda ◽  
Jonathan J. Gregory ◽  
Tomohiro Fujiwara ◽  
Seggy Abudu
Keyword(s):  
Local Recurrence ◽  
Histological Grade ◽  
Radical Resection ◽  
Resection Margins ◽  
Free Survival ◽  
Secondary Chondrosarcoma ◽  
Grade Ii ◽  
Definitive Surgery ◽  
Local Recurrence Free Survival

Aims The aim of this study was to report the outcomes of patients who underwent definitive surgery for secondary chondrosarcomas arising from osteochondromas. Patients and Methods A total of 51 patients with secondary chondrosarcomas occurring from osteochondromas were reviewed. Median age was 36 years (interquartile range (IQR) 15 to 82). Median follow-up was 6.9 years (IQR 2.8 to 10.6). The pelvis was the most commonly affected site (59%). Histological grades were grade I in 35 (69%), grade II in 13 (25%), and grade III in three patients (6%). Results Preoperative biopsy histology correctly predicted the final histological grade in 27% of patients. The ten-year disease-specific survival (DSS) for all patients was 89.4%. Local recurrence occurred in 15 patients (29%), more commonly in pelvic tumours (37%) compared with limb tumours (19%). Four patients with pelvic tumours died from progression of local recurrence. No patient with limb tumours died of disease. Wide/radical margin was associated with improved local recurrence-free survival (p = 0.032) and local recurrence was associated with worse DSS (p = 0.005). Conclusion We recommend that a secondary chondrosarcoma arising from osteochondroma of the pelvis is resected with wide/radical resection margins. The balance between the morbidity of surgery and risk of local recurrence needs to be considered in patients with limb secondary chondrosarcomas. Cite this article: Bone Joint J 2019;101-B:1313–1320

The role of cytoreductive radical prostatectomy (cRP) in men with hormone-sensitive, metastatic prostate cancer (mPCA).

2017 ◽  
Vol 35 (6_suppl) ◽  
pp. 241-241
Author(s):  
Axel Heidenreich ◽  
Nicola Fossati ◽  
Nazareno Suardi ◽  
Francesco Montorsi ◽  
Jeffrey Karnes ◽  
...  
Keyword(s):  
Functional Outcome ◽  
Oncologic Outcome ◽  
High Volume ◽  
Free Survival ◽  
Visceral Metastases ◽  
Hormone Sensitive ◽  
Extent Of Disease ◽  
Descriptive Statistical Analysis

241 Background: Androgen deprivation represents the standard treatment for PCA with osseous metastases. We explored the role of cRP in the largest cohort of contemporary patients with mPCA treated in 4 tertiary referral centres. Methods: A total of 114 patients with mPCA, lymph node, osseous or visceral metastases underwent cRP. Surgery related complications (Clavien-Dindo classification) and functional outcome were analysed. Oncologic outcome parameters such as cancer specific & overall survival as well as biochemical and clinical-free survival were evaluated using descriptive statistical analysis. Results: Mean patient age was 61 (42-69) years. Mean and median follow-up was 39.7 months (7-75) and 47 months (28-96), resp. 93 (81.6%) and 21 (18.4%) patients had low volume and high volume mets, resp.,. 80(70.2%) pts underwent neoadjuvant ADT with LHRH analogues. Surgical approach was open retropubic RP in 104 (92%) pts and 2 (1.8%), 10 (8.8%) and 101 (89.4%) pts underwent no, limited or extended pelvic LAD, resp. Adjuvant therapy was delivered in 99 (86.8%) pts. Pathohistology revealed significant vital PCA in 100% of cases: n = 16 (14.0%) exhibited pT4a, n = 21 (18.4%) had pT2 and the remainder had pT3a/b PCA. Positive lymph nodes or positive surgical margins were identified in 61.6% and 36.8%, resp.. 110 (96.5%) are alive and 66.7% are relapse-free. 74 (64.9%) pts did not experience any surgery related complications; 15 (13.1%) pts experienced Clavien Dindo grade IIIb/IV complications and underwent reintervention. Low versus high volume (32.2% vs 50%, p = 0.03), PSA at cRP < 1ng/ml vs PSA > 4 ng/ml, (18.9% vs 45.6%, p = 0.02) were associated with relapse. Low vs high volume disease (7.1% vs 32.1%), PSA < 4ng/ml vs PSA > 4 ng/ml (6.1% vs 47.8%) and neoadjuvant vs no neoadjuvant therapy (8.75% vs 24.2%) were associated with Clavien-Dindo IIIB complications (p < 0.05). Conclusions: cRP is feasible in men with mPCA independent on the extent of disease with a low rate of significant complications and good functional outcome. About two thirds of the patients remain relapse-free after a median follow-up of close to 4 years. cRP might be an individualized treatment option in the multimodality management of mPCA.

Neoadjuvant denosumab

2019 ◽  
Vol 101-B (2) ◽  
pp. 170-177 ◽  
Author(s):  
A. Puri ◽  
A. Gulia ◽  
P. Hegde ◽  
V. Verma ◽  
B. Rekhi
Keyword(s):  
High Risk ◽  
Local Recurrence ◽  
Local Control ◽  
Giant Cell Tumour ◽  
Recurrence Free Survival ◽  
Free Survival ◽  
The Mean ◽  
Mean Time ◽  
Local Recurrence Free Survival

Aims The aims of this study were to evaluate the efficacy of preoperative denosumab in achieving prospectively decided intention of therapy in operable giant cell tumour of bone (GCTB) patients, and to document local recurrence-free survival (LRFS). Patients and Methods A total of 44 patients received preoperative denosumab: 22 to facilitate curettage, 16 to facilitate resection, and six with intent of converting resection to curettage. There were 26 male and 18 female patients. The mean age was 27 years (13 to 47). Results The mean number of denosumab treatments was five (2 to 7) per patient. In 42 of 44 patients (95%), denosumab helped to achieve prospectively decided intention. A total of 41 patients were available for follow-up at a mean follow-up of 34 months (24 to 48). There were 12 local recurrences (29%), in 11 patients (11/25, 44%) who had curettage and in one patient (1/16, 6%) who had resection. The mean time to local recurrence was 16 months (8 to 25). The LRFS was 76% at two years: 94% for cases with resection and 64% for cases with curettage (p = 0.013). Conclusion Although local control rates are unlikely to improve with use of preoperative denosumab, a short preoperative course of denosumab can facilitate surgery in certain cases of operable GCTB, with a high risk of local recurrence making curettage or resection technically easier. It may also help in converting a lesion requiring resection to a lesion that could possibly be treated with curettage.

Robot-assisted radical cystectomy (RARC) versus open radical cystectomy (ORC): Oncological outcomes in 469 patients with a mean follow-up of five years.

2019 ◽  
Vol 37 (7_suppl) ◽  
pp. 492-492
Author(s):  
Kassem Faraj ◽  
Kyle Rose ◽  
Haidar Abdul-Muhsin ◽  
Anojan Navaratnam ◽  
Michael Patton ◽  
...  
Keyword(s):  
Overall Survival ◽  
Radical Cystectomy ◽  
High Volume ◽  
Recurrence Free Survival ◽  
Free Survival ◽  
Patient Demographics ◽  
Primary Bladder ◽  
Open Radical Cystectomy

492 Background: There is scant information about intermediate and long-term comparative outcomes between RARC and ORC, with the exception of a recent, small randomized-trial. We present our experience with RARC and ORC in managing bladder cancer patients who require cystectomy. Methods: A query of all patients who underwent radical cystectomy for a primary bladder tumor between 01/2007 and 6/2017 at our institution yield 469 patients. Data was collected on patient demographics, pre-operative information, operative details, pathology, and follow-up. Most RARCs were performed by a high-volume robotic surgeon who preferentially used the robotic approach at the start of all cases. Statistical analyses were generated using SPSS 22.0. Any open conversions were analyzed in the RARC cohort. Results: In 469 total patients, 197 (42.0%) and 272 (58.0%) underwent RARC and ORC, respectively. There were 163 (82.7%) and 224 (82.4%) males in each group and the mean ages (SD) were 71.5 (8.6) and 70.2 (10.5) years. Mean follow-up (SD) was 75 (37.7) and 61 (35.7) months, respectively. There were 130 (66.0%) and 172 (63.2%) patients who presented with T2 or greater disease (p=0.605). Soft-tissue margin rates were 4.1% for RARC and 6.7% for ORC patients (p=0.232). Neoadjuvant chemotherapy was used in 56.9% of RARC and 45.9% of ORC patients with ≥ cT2 disease (p=0.058). The 5-year overall survival was 60.0% vs 57.0% and the 10-year overall survival was 40.3% vs 44.8% for RARC vs. ORC patients, respectively (p=0.283). The 5-year recurrence-free survival was survival (RFS) was 71.7% vs 65.7% and the 10-year RFS was 70.5% vs 62.3% for the RARC vs. open groups, respectively (p=0.078). Aggressive histological variants, which were associated with greater likelihood for recurrence, were more common in the ORC group (13.7 vs. 22.4% p=0.013). Atypical recurrences (i.e. peritoneal, extrapelvic nodes) occurred in 6 (3.0%) and 14 (5.1%) RARC and ORC patients, respectively (p=0.266). Conclusions: In experienced hands, intermediate and long-term outcomes of RARC appear equivalent to ORC with regards to recurrence free survival, overall survival, and risk of atypical recurrences.

scholarly journals Analisi oncologica e delle complicanze nel trattamento endoscopico mediante laser CO2 dei tumori glottici in classe T1-T2: la nostra esperienza

2016 ◽  
Vol 36 (3) ◽  
pp. 167-173
Author(s):  
A. Galli ◽  
L. Giordano ◽  
D. Sarandria ◽  
D. Di Santo ◽  
M. Bussi
Keyword(s):  
Disease Free Survival ◽  
Disease Specific Survival ◽  
Free Survival ◽  
Sono Stati ◽  
Disease Free ◽  
Chirurgia Endoscopica ◽  
Disease Specific

Esistono numerose strategie terapeutiche per il trattamento del carcinoma glottico in stadio iniziale (Tis/T1/T2): la laringectomia parziale a cielo aperto, la radioterapia e la chirurgia endoscopica condotta mediante laser CO2. In particolare quest’ultimo approccio ha gradualmente, ma inesorabilmente, acquisito un ruolo sempre più centrale nel management del cancro laringeo. In questo lavoro presentiamo la nostra esperienza in materia di chirurgia endoscopica laser-assistita delle neoplasie glottiche in stadio iniziale. è stata realizzata un’analisi retrospettiva su un campione di 72 pazienti affetti da carcinoma glottico in classe T1-T2 trattati con cordectomia laser endoscopica nel periodo compreso tra il 2006 e il 2012. Tutti i pazienti avevano almeno 36 mesi di follow-up. La disease-specific survival, la disease-free survival (DFS) e il tasso di preservazione laringea rilevati con il presente studio sono stati rispettivamente del 98,6%, 84,7% e 97,2%. Analizzando l’influenza sull’outcome oncologico a lungo termine di alcune tra le principali caratteristiche della malattia o del trattamento eseguito, abbiamo riscontrato come il coinvolgimento da parte del tumore della commissura anteriore e lo staging patologico della neoplasia (pT) correlino significativamente con un aumentato tasso di recidiva locale (p = 0,021 e p = 0,035) e con una ridotta DFS (p = 0,017 e p = 0,023). Gli altri parametri presi in esame, come staging clinico, tipo di cordectomia, coinvolgimento di altre specifiche sottosedi laringee e stato dei margini di resezione, non si sono dimostrati, invece, correlare significativamente con gli endpoint oncologici stabiliti. La chirurgia endoscopica laser-assistita è quindi una tecnica estremamente affidabile per il trattamento dei tumori glottici in stadio iniziale in termini di outcome oncologico. Il tasso di recidiva risulta significativamente influenzato dal coinvolgimento della commissura anteriore e dal pT.

Sign in / Sign up

Export Citation Format

Share Document